Elsevier Inc.

SHERPA: Unknown

People

  1. Kris
    Kris
  2. Riely
    Riely
  3. Ginsberg
    Ginsberg
  4. Miller
    Miller
  5. Ladanyi
    Ladanyi
  6. Chaft
    Chaft
  7. Rusch
    Rusch
  8. Varghese
    Varghese

Groups

  1. Department of Medicine (5)
  2. Solid Tumor Oncology Division (5)
  3. Thoracic Oncology (5)
  4. Body Imaging Service (3)
  5. Radiology, Department of (3)
  6. GSK Faculty (2)
  7. Human Oncology and Pathogenesis Program (2)
  8. Tow Center for Developmental Oncology (TCDO) (2)
  9. Center for Pancreatic Cancer Research (1)
  10. Gastrointestinal Oncology Service (1)
Search Within
  1. "Gregory Riely"
  2. "Melissa Johnson"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (1)
Groups
  1. Department of Medicine (5)
  2. Solid Tumor Oncology Division (5)
  3. Thoracic Oncology (5)
  4. Body Imaging Service (3)
  5. Radiology, Department of (3)
  6. GSK Faculty (2)

More Groups

People
  1. Gregory Riely (5)
  2. Mark Kris (5)
  3. Melissa Johnson (5)
  4. Camelia Sima (3)
  5. Christopher Azzoli (3)
  6. Michelle Ginsberg (3)

More People

Years
  1. 2013 (1)
  2. 2011 (3)
  3. 2009 (1)
Publications
  1. Journal of Thoracic Oncology (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers
    Journal Article

    Varghese, A. M.; Sima, C. S.; Chaft, J. E.; Johnson, M. L.; Riely, G. J.; Ladanyi, M.; Kris, M. G.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations
    Journal Article

    Riely, G. J.; Johnson, M. L.; Medina, C.; Rizvi, N. A.; Miller, V. A.; Kris, M. G.; Pietanza, M. C.; Azzoli, C. G.; Krug, L. M.; Pao, W.; more...
    Journal of Thoracic Oncology (2011)

    Fulltext@MSK | Save
  • Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib
    Journal Article

    Johnson, M. L.; Riely, G. J.; Rizvi, N. A.; Azzoli, C. G.; Kris, M. G.; Sima, C. S.; Ginsberg, M. S.; Pao, W.; Miller, V. A.
    Journal of Thoracic Oncology (2011)

    Fulltext@MSK | Save
  • Frequency of EGFR and KRAS mutations in lung adenocarcinomas in african americans
    Journal Article

    Reinersman, J. M.; Johnson, M. L.; Riely, G. J.; Chitale, D. A.; Nicastri, A. D.; Soff, G. A.; Schwartz, A. G.; Sima, C. S.; Ayalew, G.; Lau, C.; more...
    Journal of Thoracic Oncology (2011)

    Fulltext@MSK | Save
  • Phase II trial of dasatinib for patients demonstrating acquired resistance to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib (E) or gefitinib (G)
    Meeting Abstract

    Johnson, M. L.; Riely, G. J.; Rizvi, N. A.; Azzoli, C. G.; Kris, M. G.; Ginsberg, M. S.; Pao, W.; Miller, V. A.
    Journal of Thoracic Oncology (2009)

    Fulltext@MSK | Save